August 8, 2007 — Arrowhead Research Corp. and Paragon Intellectual Properties LCC have announced that Arrowhead’s majority-owned subsidiary, Unidym Inc., has signed an exclusive license agreement with Paragon’s majority-owned subsidiary, Nanotech Catheter Solutions, LLC (NCS). NCS will use Unidym’s carbon nanotube technology in the development of medical devices for the treatment of cardiovascular disease. Under the terms of the agreement, Unidym will receive a 20% equity stake in NCS, and the parties will negotiate a supply agreement or royalty.

According to Unidym’s new CEO, Art Swift, “This agreement marks the launch of Unidym’s licensing program. Our goal is to license our intellectual property and/or supply nanotubes to third parties commercializing products incorporating carbon nanotubes outside of our focus of electronics. We intend to replicate this model in other areas such as nanotube-based therapeutics, diagnostics, field emission displays, nonvolatile memory, and composite materials.”